11 results about "Vascular aneurysm" patented technology

An intra-vascular aneurysm-treatment stent and a method for lowering pressure within an aneurysm bubble in a blood vessel. A stent coil is insertable into a blood vessel, the coil made of a material sufficiently flexible to move around curves, loops, and corners in the blood vessel. The stent coil is positioned in the blood vessel with selected stent coil portions proximate an opening into either a saccular aneurysm or a fusiform aneurysm. Blood in the lumen of the blood vessel flows past the leading edges and both over the outer surfaces, and under the inner surfaces. A portion of the blood inside the aneurysm becomes entrained with the blood flowing over the outer surfaces. At the trailing edges, the converging blood flows create eddies.

There are provided methods, systems and non-transitory storage mediums for classifying aneurysms in a blood vessel of a given patient. Medically acquired images representing a blood vessel over a portion of the cardiac cycle are received. The images are segmented to obtain segmented anatomical structures of the wall and the lumen of the blood vessel. The volumetric changes of the outer wall and the lumen are calculated over the portion of the cardiac cycle. The volumetric changes of the thrombus are calculated based on the volumetric changes of the outer wall and the lumen. The aneurysm is classified as one four types based at least on the volumetric changes of the lumen and the thrombus. This classification may be used to assess the severity of the aneurysm.

Methods, compositions, and devices for treating a vascular aneurysm, including an abdominal aortic aneurysm, are disclosed. In particular, the various embodiments relate to a method of treating an abdominal aortic aneurysm by increasing the mechanical stiffness of an aortic segment adjacent to the abdominal aortic aneurysm in a subject. The mechanical stiffness of the adjacent aortic segment may be increased, for example, by applying a surgical adhesive or intravascular stent. Such treatment reduces stress on the aortic wall and limits further growth of the abdominal aortic aneurysm.

This invention discloses an artificial intelligence-based method for measuring aneurysms in cranial arterial angiography images, comprising the following steps: S1, acquiring keyframes of DSA images; S2, segmenting the keyframes using a deep neural network to distinguish between the background and blood vessels; S3, determining the aneurysm location region based on the segmentation results, obtaining the contour of the region, and simultaneously obtaining the length of the connection between the gray aneurysm region and the white blood vessel region, i.e., the aneurysm diameter width w; S4, based on the obtained aneurysm contour shape, calculating the aneurysm centroid O by spatial moments, drawing a perpendicular line through the centroid O and intersecting the contour boundary, traversing all angles, and taking the largest intersection line segment as the maximum diameter l of the aneurysm, drawing a perpendicular line from the aneurysm diameter width w and intersecting the contour boundary, the maximum height of which is the aneurysm height h. This invention achieves fully automated measurement of the diameter of cerebral vascular aneurysms through a deep neural network trained on a large amount of data, solving the problems of slow speed, poor accuracy, and large influence of subjective factors in manual measurement.

Disclosed herein are medical devices comprising a single-lobed, thin-walled, expandable body (“ballstent” or “blockstent”) and a flexible, elongated delivery device (“delivery catheter”) and systems and methods of use for treating saccular vascular aneurysms and methods of use for occluding segments of blood vessels and other biological conduits.Expandable bodies comprising gold, platinum, or silver that can be compressed, positioned in the lumen of an aneurysm or blood vessel, and expanded to conform to the shape of the aneurysm or segment of blood vessel or biological conduit are disclosed. The external surface of the expandable bodies can be configured to promote local thrombosis and to promote the growth of tissue into and around the wall in order to reduce migration of the expandable body and to occlude and seal the aneurysm or biological conduit. The wall of the expandable bodies can also be configured to release drugs or pharmacologically active molecules, such as those that promote thrombosis, cell proliferation, extracellular matrix deposition, or tissue ingrowth.

Medical device (2) for treating aneurysms in cerebral blood vessels, comprising a compressible and expandable lattice structure (10) made of lattice elements (11, 12, 13, 14) forming cells (15), wherein the lattice structure (10) comprises, at least in sections, a cover (16) made of an electrospun fabric, which, in an implanted state of the lattice structure (10), reduces the blood flow through the hollow body organ by means of the lattice structure (10) in the region of the cover (16), wherein the lattice structure (10) is formed with a taper (23) in a central region (20), and wherein at least the central region (20) comprises the cover (16), wherein the cover (16) has a porosity with pores having a size of at most 750 µm 2 and on an area of ​​100,000 µm 2 at least 15 pores with a size of at least 30 µm 2and wherein the cover (16) has a blood-permeable and a blood-impermeable area.

An intra-vascular aneurysm-treatment stent and a method for lowering pressure within an aneurysm bubble in a blood vessel. A stent coil is insertable into a blood vessel, the coil made of a material sufficiently flexible to move around curves, loops, and corners in the blood vessel. The stent coil is positioned in the blood vessel with selected stent coil portions proximate an opening into either a saccular aneurysm or a fusiform aneurysm. Blood in the lumen of the blood vessel flows past the leading edges and both over the outer surfaces, and under the inner surfaces. A portion of the blood inside the aneurysm becomes entrained with the blood flowing over the outer surfaces. At the trailing edges, the converging blood flows create eddies.

Compounds, methods, and pharmaceutical compositions are provided for reducing the amount or activity of AGT RNA and, in some instances, the amount of AGT in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful for ameliorating at least one symptom or sign of cardiovascular disease. Such compounds and pharmaceutical compositions are useful for ameliorating at least one symptom or sign of a disease or disorder associated with the RAAS pathway. Such symptoms and markers include hypertension, chronic kidney disease, stroke, myocardial infarction, heart failure, heart valvular disease, vascular aneurysm, peripheral arterial disease, and organ injury. Such cardiovascular diseases include hypertension, refractory hypertension, Marfan syndrome and heart failure.

A non-occlusive device is provided that includes a coilable section and a docking section. When deployed from a microcatheter within a wide-neck vascular aneurysm, the coilable section is configured to become coiled into a coil defining a sequence of concentric loops, and to bridge a neck of the aneurysm so as to at least partially cover an orifice of the aneurysm, when in use. The docking section is configured to be deployed from the microcatheter within the aneurysm. The docking section extends distally from an outermost one of the concentric loops of the coil, and is shaped so as to define one loop or a plurality of concentric loops having an outer diameter less than an outer diameter of the concentric loops of the coil. The docking section is configured to anchor, stabilize, and / or assist with positioning of the device within the aneurysm. Other embodiments are also described.

The utility model discloses a variable-diameter dense net support, and relates to the technical field of medical instruments. Comprising at least one variable-diameter dense net outer stent and an equal-diameter dense net stent, the diameter of the dense net outer stent is gradually reduced in the length direction, the diameter of the near end of the outer stent is larger than that of the far end of the outer stent, and the opposite ends of the near end and the far end expand outwards in a horn mouth shape. The diameter of each part of the dense net outer stent is reasonably designed, so that the dense net outer stent can better adapt to the characteristic that the near end of a blood vessel is thick and the far end is thin, has better adherence and more appropriate supporting force, and remarkably changes the flow state of blood flow in aneurysm and reduces the impact of the blood flow on the aneurysm by utilizing the principle of haemodynamics on the premise of not influencing the flow state of blood flow of other communicated blood vessels; and endothelial cells grow along the stent skeleton, the neck of the aneurysm is gradually repaired, the aneurysm is cured, and the stent is specially used for complex aneurysm with high treatment difficulty, such as large, giant or Y-type or X-type vascular aneurysm which is not suitable for clipping or embolism due to too small aneurysm, and has a wide application prospect.

Compounds, methods, and pharmaceutical compositions are provided for reducing the amount or activity of AGT RNA and, in some instances, the amount of AGT in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful for ameliorating at least one symptom or sign of cardiovascular disease. Such compounds and pharmaceutical compositions are useful for ameliorating at least one symptom or sign of a disease or disorder associated with the RAAS pathway. Such symptoms and markers include hypertension, chronic kidney disease, stroke, myocardial infarction, heart failure, heart valvular disease, vascular aneurysm, peripheral arterial disease, and organ injury. Such cardiovascular diseases include hypertension, refractory hypertension, Marfan syndrome and heart failure.